Results 11 to 20 of about 676 (157)

A randomized study of solriamfetol for excessive sleepiness in narcolepsy [PDF]

Annals of Neurology, 2019
ObjectiveSolriamfetol (JZP‐110) is a selective dopamine and norepinephrine reuptake inhibitor with wake‐promoting effects. This phase 3 study (NCT02348593) evaluated the safety and efficacy of solriamfetol in narcolepsy.MethodsPatients with narcolepsy with mean sleep latency <25 minutes on the Maintenance of Wakefulness Test (MWT), Epworth ...
Thorpy M. J., Shapiro C., Mayer G., Corser B. C., Emsellem H., Plazzi G., Chen D., Carter L. P., Wang H., Lu Y., Black J., Dauvilliers Y.   +11 more
openaire   +6 more sources

Activated wake systems in narcolepsy type 1 [PDF]

Annals of Neurology, Volume 94, Issue 4, Page 762-771, October 2023., 2023
ObjectiveNarcolepsy type 1 (NT1) is assumed to be caused solely by a lack of hypocretin (orexin) neurotransmission. Recently, however, we found an 88% reduction in corticotropin-releasing hormone (CRH)-positive neurons in the paraventricular nucleus (PVN)
Anink, J., Balesar, R., Breesuwsma, N., Dekker, F. den, Fronczek, R., Harteman, Z., Lammers, G.J., Linssen, S., Shan, L., Shuker, L., Swaab, D.F., Zhou, J.R.   +11 more
core   +3 more sources

481 Solriamfetol Titration & AdministRaTion (START): Characteristics of patients with narcolepsy and solriamfetol prescriber rationale [PDF]

Sleep, 2021
Abstract Introduction Pharmacotherapy for excessive daytime sleepiness (EDS) associated with narcolepsy is diverse, with factors such as efficacy, side effects, and tolerance influencing treatment decisions.
Michael Thorpy, Danielle Hyman, Gregory Parks, Abby Chen, Catherine Foley, Diane Ito, Haramandeep Singh   +6 more
openaire   +2 more sources

Effects of solriamfetol on on-the-road driving in participants with narcolepsy: A randomised crossover trial. [PDF]

Hum Psychopharmacol, 2023
Abstract Objective To evaluate the impact of solriamfetol, a dopamine and norepinephrine reuptake inhibitor, on on‐the‐road driving performance in participants with narcolepsy. Methods In this randomised, double‐blind, placebo‐controlled, crossover study, driving performance during a 1 h on‐road driving test was assessed at 2 and 6 h post‐dose ...
Vinckenbosch F, Lammers GJ, Overeem S, Chen D, Wang G, Carter LP, Zhou K, Ramaekers JG, Vermeeren A.   +8 more
europepmc   +2 more sources

P148 Solriamfetol Titration & AdministRaTion (START): Dosing and titration strategies in patients with narcolepsy starting solriamfetol [PDF]

SLEEP Advances, 2021
Abstract Introduction Solriamfetol (Sunosi) is a dopamine/norepinephrine reuptake inhibitor approved (EU/US) to treat excessive daytime sleepiness (EDS) in adults with narcolepsy (75–150 mg/day) or obstructive sleep apnoea (OSA) (37.5–150 mg/day).
Thorpy, M, Hyman, D, Parks, G, Chen, A, Foley, C, Ito, D, Singh, H   +6 more
openaire   +1 more source

Trends and variation in issuance of high-cost narcolepsy drugs by NHS England organisations and regions from 2019 to 2022. [PDF]

J Sleep Res
Summary Clinicians and people with narcolepsy report varied access to higher‐cost narcolepsy treatments in England associated with variations in national and local commissioning. There are no publicly available data quantifying use of these drugs to support policy decisions. We therefore aimed to describe national, regional and local prescribing trends
van Someren F, Wiedemann M, Warren-Gash C, Sykorova M, Mistry H, Miller MA, Leschziner G, Nolte E, Belot A, Smith IE, Quinnell T, Eriksson SH, Strongman H.   +12 more
europepmc   +2 more sources

Clinical characteristics of a large cohort of patients with narcolepsy candidate for pitolisant: a cross-sectional study from the Italian PASS Wakix® Cohort [PDF]

, 2022
Introduction: Narcolepsy is a chronic and rare hypersomnia of central origin characterized by excessive daytime sleepiness and a complex array of symptoms as well as by several medical comorbidities.
Agostoni E. C., Blanchard N., Bonanni E., Brunetti V., Centonze D., Cicolin A., Della Marca G., Ferini-Strambi L., Ferri R., Figorilli M., Gigli G. L., Izzi F., Lecomte I., Liguori C., Liguori R., Lodi R., Mutti C., Nobili L., Parrino L., Pedrazzi G., Pizza F., Placidi F., Plazzi G., Proserpio P., Puligheddu M., Romigi A., Sacco T., Savarese M. A., Terzaghi M.   +28 more
core   +5 more sources

Incidence and duration of common early-onset adverse events in randomized controlled trials of solriamfetol for treatment of excessive daytime sleepiness in obstructive sleep apnea and narcolepsy. [PDF]

, 2022
Study objectivesThis post hoc analysis characterized the weekly incidence and overall duration of common early-onset, treatment-emergent adverse events (TEAEs) during solriamfetol treatment.MethodsParticipants (obstructive sleep apnea [OSA], n = 474 ...
Bujanover, Shay, Dauvilliers, Yves, Gotfried, Mark, Malhotra, Atul, Rosenberg, Russell, Scheckner, Brian, Schweitzer, Paula K, Thorpy, Michael J, Zammit, Gary   +8 more
core   +2 more sources

Investigation and management of residual sleepiness in CPAP-treated patients with obstructive sleep apnoea: the European view [PDF]

, 2022
Excessive daytime sleepiness (EDS) is a major symptom of obstructive sleep apnoea (OSA), defined as the inability to stay awake during the day. Its clinical descriptors remain elusive, and the pathogenesis is complex, with disorders such as insufficient
Asin, Jerryll, Barbé Illa, Ferran, Bonsignore, Maria R., Caussé, Christian, Craig, Sonya, Pepin, Jean Louis, Randerath, Winfried, Verbraecken, Johan   +7 more
core   +1 more source

Obstructive Sleep Apnoea Treatments-Where Are We Now? [PDF]

Respirology
Respirology, Volume 30, Issue 10, Page 920-922, October 2025.
Luu S, Lee D, Yee BJ.
europepmc   +2 more sources